Published December 2013 | Version v1
Journal article

The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis

  • 1. Mount Sinai School of Medicine, Department of Radiology, New York, NY (United States)
  • 2. Mount Sinai School of Medicine, Translational and Molecular Imaging Institute, One Gustave L. Levy Place, Box 1234, New York, NY (United States)
  • 3. Harvard University - MIT - Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA (United States)
  • 4. Hopital Pitie Salpetriere, Paris (France)
  • 5. Harvard Medical School and Massachusetts General Hospital, Boston, MA (United States)
  • 6. University of Sydney, George Institute, Sydney (Australia)
  • 7. Rheinisch-Westfaelische Technische Hochschule Aachen, Department of Nuclear Medicine, Aachen (Germany)
  • 8. Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands)
  • 9. Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands)
  • 10. Mount Sinai School of Medicine, Biostatistics Shared Research Facility, New York, NY (United States)
  • 11. F. Hoffmann-La Roche Ltd, Basel (Switzerland)
  • 12. Peter Munk Cardiac Centre and Li Ka Shing Knowledge Institute, Toronto (Canada)
  • 13. Mount Sinai School of Medicine, Cardiovascular Institute, New York, NY (United States)
  • 14. The Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid (Spain)
  • 15. University of Cambridge, Division of Cardiovascular Medicine, Cambridge (United Kingdom)

Description

Inflammation and neovascularization in vulnerable atherosclerotic plaques are key features for severe clinical events. Dynamic contrast-enhanced (DCE) MRI and FDG PET are two noninvasive imaging techniques capable of quantifying plaque neovascularization and inflammatory infiltrate, respectively. However, their mutual role in defining plaque vulnerability and their possible overlap has not been thoroughly investigated. We studied the relationship between DCE-MRI and 18F-FDG PET data from the carotid arteries of 40 subjects with coronary heart disease (CHD) or CHD risk equivalent, as a substudy of the dal-PLAQUE trial (NCT00655473). The dal-PLAQUE trial was a multicenter study that evaluated dalcetrapib, a cholesteryl ester transfer protein modulator. Subjects underwent anatomical MRI, DCE-MRI and 18F-FDG PET. Only baseline imaging and biomarker data (before randomization) from dal-PLAQUE were used as part of this substudy. Our primary goal was to evaluate the relationship between DCE-MRI and 18F-FDG PET data. As secondary endpoints, we evaluated the relationship between (a) PET data and whole-vessel anatomical MRI data, and (b) DCE-MRI and matching anatomical MRI data. All correlations were estimated using a mixed linear model. We found a significant inverse relationship between several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. Regarding our secondary endpoints, there was a significant relationship between plaque burden measured by anatomical MRI with several perfusion indices by DCE-MRI and 18F-FDG uptake by PET. No relationship was found between plaque composition by anatomical MRI and DCE-MRI or 18F-FDG PET metrics. In this study we observed a significant, weak inverse relationship between inflammation measured as 18F-FDG uptake by PET and plaque perfusion by DCE-MRI. Our findings suggest that there may be a complex relationship between plaque inflammation and microvascularization during the different stages of plaque development. 18F-FDG PET and DCE-MRI may have complementary roles in future clinical practice in identifying subjects at high risk of cardiovascular events. (orig.)

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-013-2518-4

Additional details

Identifiers

Publishing Information

Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Journal Volume
40
Journal Issue
12
Journal Page Range
p. 1884-1893
ISSN
1619-7070